Compare Abbott Laboratories (ABT) vs ServiceNow Inc (NOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ServiceNow Inc — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while ServiceNow Inc trades at $107.18 (market cap $114.20B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| ABT | NOW | |
|---|---|---|
Market Cap | $166.94B | $114.20B |
Sector | Health | Technology |
52-Week High | $136.62 | $204.60 |
52-Week Low | $82.57 | $83.00 |
Enterprise Value | $193.69B | $111.45B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ServiceNow (NOW) trades at $107.93, up 1.51% today, with a bullish technical outlook supported by positive moving averages. The company reported strong revenue growth to $13.28 billion in 2025 and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth potential and conference presentations, while analyst consensus remains strongly bullish with an 85.51% buy rating.
The outlook for NOW is positive due to robust fundamentals and AI adoption, but high valuation multiples (P/E 64.24) pose a risk if growth slows. Upside to the $136.43 price target offers potential, yet investors face volatility from competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
